8VI (ASX:8VI) - Chairman, Clive Tan
Chairman, Clive Tan
Source: 8VI Holdings
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Singapore-based ‘FinEduTech’ company 8VI (8VI) is still exploring plans for a secondary listing on the Singapore Stock Exchange
  • The company revealed its proposal on June 8, saying the group would take until the last quarter of 2021 to decide
  • The secondary listing would allow Singaporean and Malaysian investors and clients to participate in and benefit from 8VI’s growth
  • Shares in 8VI remain steady today at $4 each as of 1:06 pm AEDT

Singapore-based ‘FinEduTech’ company 8VI (8VI) says it’s still exploring plans for a secondary listing on the Singapore Stock Exchange.

The company announced its proposal on June 8, saying the group would take until the last quarter of 2021 to decide.

According to the most recent announcement, the decision is still being assessed with no new deadline revealed.

The June announcement claimed the reason for a secondary listing was to allow Singaporean and Malaysian investors and clients to participate in and benefit from 8VI’s growth.

The board said the secondary listing would also boost credibility with regulators and strategic partners close to home.

Shares in 8VI remain steady today at $4 each as of 1:06 pm AEDT.

8VI by the numbers
More From The Market Online

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think…
The Market Online Video

Market Close: ASX signs off on a sigh with all sectors red-lining

The ASX200 finished 1.3 per cent down with every sector in the red and Industrials and Real Estate brittle and bruised as bot…
The Market Online Video

Market Update: ASX on red alert with all sectors below the surface

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.